CTLA4 and melanoma: By analyzing a melanoma cohort (database of Genotypes and Phenotypes (dbGaP) accession number: phs000452.v2.p1) with RNA-seq data and anti-CTLA4 (ipilimumab) therapy response information available from 42 patients28, we found that patients with low TIR risk scores had a higher anti-CTLA4 response rate than patients with high TIR scores (chi-square test, P = 0.03, Fig. 5a).